CHAPTER 9 ANTI-CANCER ACTIVITY OF COMPOUND-III

Similar documents
THE UNIVERSITY OF NEWCASTLE- DISCIPLINE OF MEDICAL BIOCHEMISTRY. STANDARD OPERATING PROCEDURE PROCEDURE NO: GLP 079 MOD: 1st Issue Page: 1 of 7

LABORATORY 2 Staining and processing of blood parasites Differential counts of leukocytes (giemsa stains)

Preparation of Blood Films

Collect and label sample according to standard protocols. Gently invert tube 8-10 times immediately after draw. DO NOT SHAKE. Do not centrifuge.

Cardiovascular System. Blood Components

GYAN VIHAR UNIVERSITY

Urinalysis and Body Fluids CRg. Synovial Fluid. Synovial Fluid. Unit 4. Composition and formation. Functions. Reasons for analysis.

ABO-Rh Blood Typing Using Neo/BLOOD

Fighting the Battles: Conducting a Clinical Assay

STAINING OF PBF AND INTERPRETATION OF NORMAL AND ABNORMAL RED CELL MORPHOLOGY

Urinalysis and Body Fluids CRg

INMA LABORATORY MANUAL

Laboratory 12 Blood Cells

CMP Antibody Production Service

AAGPs TM Anti-Aging Glyco Peptides. Enhancing Cell, Tissue and Organ Integrity Molecular and biological attributes of lead AAGP molecule

Yvette Marie Miller, M.D. Executive Medical Officer American Red Cross October 20, th Annual Great Lakes Cancer Nursing Conference Troy, MI

Beaumont Hospital Department of Nephrology and Renal Nursing. Guideline for administering Ferinject

Lab 02: Blood Cytology (20 points)


WHICH SAMPLES SHOULD BE SUBMITTED WHEN LYMPHOID NEOPLASIA IS SUSPECTED?

Effects of Two Proprietary Compounds in Multiple Sclerosis DATE

MagExtractor -Genome-

Minimal residual disease detection in Acute Myeloid Leukaemia on a Becton Dickinson flow cytometer

Quality Assurance in Blood Cell Labelling

EDUCATIONAL COMMENTARY RED BLOOD CELLS AND WHITE BLOOD CELLS IN URINALYSIS

THE CANCER STEM CELL INHIBITORS VS-6063 AND VS-5584 EXHIBIT SYNERGISTIC ANTICANCER ACTIVITY IN PRECLINICAL MODELS OF MESOTHELIOMA

UNIVERSIDAD DE GUAYAQUIL DEPARTMENT OF CHEMICAL SCIENCES

Protein extraction from Tissues and Cultured Cells using Bioruptor Standard & Plus

Exercise 9: Blood. Readings: Silverthorn 5 th ed, , ; 6 th ed, ,

UNIVERSIDAD DE GUAYAQUIL DEPARTMENT OF CHEMICAL SCIENCES

Thibodeau: Anatomy and Physiology, 5/e. Chapter 17: Blood

CHAPTER 2 MATERIALS AND METHODS

UNIVERSIDAD DE GUAYAQUIL DEPARTMENT OF CHEMICAL SCIENCES

STANDARD OPERATING PROCEDURE

Clinical Laboratory Parameters for Crl:CD(SD) Rats. March, Information Prepared by Mary L.A. Giknis, Ph.D. Charles B. Clifford, D.V.M., Ph.D.

Hepatitis C. Laboratory Tests and Hepatitis C

HP8 herbal formula selectively inhibits prostate cancer cell line proliferation by inducing G2/M cell cycle arrest.

TOTAL PROTEIN FIBRINOGEN

Characteristics of Living Things illustrate and explain that the cell is a living system that exhibits all the characteristics of life

What Does My Bone Marrow Do?

Summary & Conclusion

Explain the role of blood and bloodstain patterns in forensics science. Analyze and identify bloodstain patterns by performing bloodstain analysis

White Blood Cells (WBCs) or Leukocytes

serology Agglutination Techniques and Blood Cell Identification

Determinants of Blood Oxygen Content Instructor s Guide

Developmental Validation of a Novel Lateral Flow Strip Test for Rapid Identification of Human Blood, Rapid Stain Identification-Blood, RSID -Blood

Chromatin Immunoprecipitation

Measuring Cell Viability/Cytotoxicity: Cell Counting Kit-F

1. BLOOD GROUP SYSTEMS. Page 1. Haematology LECTURE 10. BLOOD GROUPS AND TRANSFUSIONS OVERVIEW. 1. Blood Group Systems

Standard Operating Procedure

Introduction. Case History

Biology 29 Cell Structure and Function Spring, 2009 Springer LABORATORY 2:CHLOROPLASTS AND PHOTOREDUCTION

RDW-- Interpreting the Full Blood Count

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

EdU Flow Cytometry Kit. User Manual

Practice Questions 1: Scientific Method

Cold Agglutination Titer detecting Cold Reacting Antibodies

COMPARISON OF ANTIGENS IN THE OVARY, OVIDUCT AND UTERUS OF THE RABBIT AND OTHER MAMMALIAN SPECIES

EFFECT OF DAILY VERSUS WEEKLY IRON FOLIC ACID SUPPLEMENTATION ON THE HAEMOGLOBIN LEVELS OF CHILDREN 6 TO 36 MONTHS OF URBAN SLUMS OF VADODARA

Name (print) Name (signature) Period. (Total 30 points)

Interpretation of Laboratory Values

LABORATORY PROCEDURE MANUAL

RPCI 004 v.002 Staining Procedure For all Directly Conjugated Reagents (Whole Blood Method)

STEMCELL Quality Control Kits

I. ACID-BASE NEUTRALIZATION, TITRATION

Why iron and haemoglobin are important

Granulocytes vs. Agranulocytes

Cell Viability Assays: Microtitration (MTT) Viability Test Live/Dead Fluorescence Assay. Proliferation Assay: Anti-PCNA Staining

MLX BCG Buccal Cell Genomic DNA Extraction Kit. Performance Characteristics

Artemisinin in Cancer Treatment. Dr. Narendra P. Singh Department of Bioengineering University of Washington Seattle

Blood Collection and Processing SOP

Immunophenotyping peripheral blood cells

123count ebeads Catalog Number: Also known as: Absolute cell count beads GPR: General Purpose Reagents. For Laboratory Use.

THE INFLUENCE OF MOUSE-RAT PARABIOSIS ON THE GROWTH IN RATS OF A TRANSPLANT- ABLE MOUSE SARCOMA.*

EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL

VALIDATION AND QUALIFICATION

Fast, easy and effective transfection reagent for mammalian cells

And Now, Presenting...

Acute myeloid leukemia (AML)

Enzyme Action: Testing Catalase Activity

1.5 Function of analyte For albumin, see separate entry. The immunoglobulins are components of the humoral arm of the immune system.

Care Pathway for the Administration of Intravenous Iron Sucrose (Venofer )

KEY CHAPTER 14: BLOOD OBJECTIVES. 1. Describe blood according to its tissue type and major functions.

Supplemental Information. McBrayer et al. Supplemental Data

Creatine Kinase (CK) Enzymatic Assay Kit Manual Catalog #:

Hematology Reagents and Controls Our products for your critical process

BLOOD FILM STAINING EFFECTS

Human Clinical Study for Free Testosterone & Muscle Mass Boosting

AC: Doxorubicin and Cyclophosphamide

MTT Cell Proliferation Assay

Comparability of Cord Blood Units

Intraperitoneal Chemotherapy

SCANTIBODIES Laboratory, Inc. Contract Monoclonal Antibody Production

Page 1. Name: 4) The diagram below represents a beaker containing a solution of various molecules involved in digestion.

PROTOCOL. Immunostaining for Flow Cytometry. Background. Materials and equipment required.

Enzyme Action: Testing Catalase Activity

Quantitation of Drugs in Dried Bloodstains. Thomas Meyer Anna Gomenyuk Nadiah Lester

UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO Gundersen Health System Center for Cancer and

CLL. Handheld record. Stockport NHS foundation trust

NEW YORK STATE CYTOHEMATOLOGY PROFICIENCY TESTING PROGRAM Glass Slide Critique ~ November 2010

Transcription:

174 CHAPTER 9 ANTI-CANCER ACTIVITY OF COMPOUND-III 9.1 IINTRODUCTION Oleanolic acid is a naturally occurring triterpenoid, widely distributed in food and medicinal plants. It is relatively non-toxic and it exhibits antitumor, hepatoprotective and antiviral properties [132]. It exists widely in medicinal herbs and natural plants in the form of free acid or aglycones. 9.2 MATERIALS AND METHODS 9.2.1 Animals Swiss Albino mice weighing between 20-25gms were used for the study. They were maintained under standard environmental condition (temperature 25-28 0 C and 12hrs light/dark cycle) and they were allowed with standard laboratory feed and water ad libitum. The animals were given a week s time to get acclimatized with the laboratory condition. 9.2.2 Anti-Cancer Activity After acclimatization, mature male Swiss Albino mice were divided into four groups (n=10). All the groups except group I were inoculated (i.p.) with DAL Cells of 1 x 10 6 cells/mouse weekly [120]. The day of DAL administration was considered as day 0.Group I served as control and received distilled water for 14 days, group II served as DAL control group

175 were inoculated (i.p.) with DAL Cells of 1 x 10 6 cells/mouse without drug treatment. Group III animals received compound III (20mcg/kg) p.o for 14 consecutive days. On day 15, five mice of each group were sacrificed 24hrs after the last dose and the rest were kept with food and water ad libitum to check the increase in the life span of the tumor hosts. The effect of methanolic extract on tumor growth and host s survival time were examined by studying the parameters like tumor volume, tumor cell count, viable tumor cell count, nonviable tumor cell count, mean survival time and increase in life span [121]. Determination of tumor volume The fluid was collected from the peritoneal cavity of the mice. The volume was measured by taking it in a graduated centrifuge tube and packed cell volume was determined by centrifuging at 1000rpm for 5 min. Determination of tumor cell count The fluid was taken in a RBC pipette and diluted to 1000 times. Then a drop of the diluted cell suspension was placed on the Neubauer s counting chamber and the number of cells in 64 small squares were counted. Estimation of viable tumor cell count The cells were then stained with Trypan blue (0.4% in normal saline) dye. The cells that did not take up the dye were considered viable and the stained as nonviable. They were counted and the viable and non viable cell counts were estimated [122].

176 Percentage increase in life span Percentage increase in life span was calculated by observing the mortality and the effect of extract on tumor growth. The mean survival time (MST) of each group consisting of 6 mice was noted [123]. Haematological studies Blood was drawn from each mouse from tail vein under sterilised condition and the red blood cell count, haemoglobin content and white blood cell counts were determined using cell diluting fluids and a haemocytometer. Differential cell count was carried out using Leishman stained blood smears. Serum protein concentration was estimated by Lowry s method and packed cell volume was determined by the method described by Docie et al [124]. 9.2.3 Statistical Analysis The data s were expressed as mean ± SEM, statistical analysis was performed by one way ANOVA followed by Tukey-Kramer multiple comparison test, p values <0.05 were considered as significant. Highest significant difference test performed with Graph pad instat software. 9.3 RESULTS The tumor control mice the haematological parameters on day 15 were found to be significantly altered when compared to normal group. The total WBC count, protein and PCV were found to be increased with a reduction of the hemoglobin and RBC. In a differential count of WBC, the percent of neutrophils increased while the lymphocyte count decreased. The compound treated group showed significant effect on increasing life span and retrieving all the parameters to normal level.

177 Effect on mean survival time and tumor growth In the DAL control group the mean survival time was 12 ± 1.5days, while it increased to 29.2±1.7 for compound treated group (p<0.001). The increase in life span of tumor bearing mice treated with compound was found to be 70%. Treatment with compound reduced the tumor volume, packed cell volume, and viable tumor cell count in a dose-dependent manner as compared to that of DAL control group. Further, nonviable tumor cell count was increased when compared with the DAL control [Table 9.1, Figures 9.1 and 9.2]. Effect on haematological parameters The haemoglobin content and the RBC count in the DAL control group were found to be decreased when compared to normal group. The haemoglobin content for DAL treated control was found to be 6.3 ± 0.5 and treatment with the compound increased the hemoglobin content to 12.8±0.9. The RBC count to was found to be increased to more or less normal level. The total WBC counts and protein were found to be increased in DAL control group 15.1±0.5 and 16.7±0.8 when compared with normal group. Administration of compound in DAL bearing mice reduced both WBC count and protein when compared with DAL control. In the differential count of WBC, increase of neutrophils and the lymphocyte count decreased in DAL control group. Treatment with compound changed these altered parameters more or less normal [Table 9.2, Figures 9.3 and 9.4].

Table 9.1 Effect of compound III on survival time, life span, tumor volume, viable and non-viable cell count in DAL bearing mice S.No 1. 2. 3. Treatment Vehicle control (5ml/kg p.o) DAL control (x10 6 cells/ml) Compound III (20mcg/kg) Survival time (Days) Increase of life span Tumor volume (ml) Viable cell count x 10 6 cells/ml Non-viable cell count x 10 6 cells/ml 40 100 - - - 12 ± 1.5* * 10 4.15 ±0.25 * * 9.7 ±0.32 * * 1.7 ±0.74 * * 29.2±1.7 *** 70 1.1±0.85* * * 1.4 ±0.32 2.4±0.43 * * * Values are mean+ SEM expressed as (n=6) p*<0.05; **<0.01; ***<0.001; as compared with group II. p< 0.05 considered significant 178

179 120 100 80 60 40 20 0 Vehicle Control DAL control Compound III (20mcg/kg) Survival time (Days) Increase of life span Figure 9.1 Effect of compound III on survival time and increase of life span 12 10 8 6 4 2 0 Tumor volume (ml) Viable cell count Non viable cell count Vehicle Control DAL control Compound III (20mcg/kg) Figure 9.2 Effect of compound III on tumor volume, Viable cell count and Non viable count

Table 9.2 Effect of compound III on haematological parameters in DAL bearing mice S.No Treatment Hb (g/dl) RBC (106cells/mm3) WBC (103 cells/mm3 Total Protein (g/dl) PCV (mm) Differential cell count (%) Lymphocytes Neutrophils Basophils 1. 2. Vehicle control (5ml/kg p.o) DAL control (1x10 6 cells/ml) 14.3±0.2 6.5±0.5 7.5 ±0.7 8.5±0.3 16.2 ±0.4 72.6±0.9 16.8±0.5 2.1±0.2 6.3±0.5 ** 2.3±0.2*** 15.1±0.5** 16.7±0.8** * 27.4±0.2*** 33.4±0.7 * * * 46.9±0.2 * * * 3.7±0.7 Compound III 3. 12.8±0.9 *** 6.1±0.2 * * * 8.8 ±0.4 * 9.4±0.3* * 17.5±0.4*** 67.3±0.5** * 20.3±0.3** 2.4±0.5 (20mcg/kg) Values are mean+ SEM expressed as (n=6) p*<0.05; **<0.01; ***<0.001; as compared with group II. p< 0.05 considered significant 180

181 30 25 20 15 10 5 0 Hb(g%) RBC WBC Total Protein PCV Vehicle Control DAL control Compound III (20mcg/kg) Figure 9.3 Effect of compound III on Hb, RBC, WBC, total Protein and PCV 80 70 60 50 40 30 20 10 0 Lymphocytes Neutrophils Basophils Vehicle Control DAL control Compound III (20mcg/kg) Figure 9.4 Effect of compound III on differential counts

182 9.4 DISCUSSION The present study was carried out to evaluate the anti-cancer activity of compound III (20 mcg/kg) on DAL bearing mice. A reliable criteria for judging the value of any anti-cancer agent is the prolongation of life span of animals[129]. A significant increase in life span of animals was observed in the compound treated animals, the tumor volume, packed cell volume, tumor cell count and also the haematological parameters were brought back to more or less normal levels. To evaluate the extract treatment indirectly inhibited the tumor cell growth, the effect of compound treatment was examined on the viable and nonviable cell counts against tumor bearing mice. The treatment with the compound was found to enhance the non-viable cell count and decrease the viable cell count. It may be due to the absorption of extract by viable cells which leads the lysis of the cells through the activation of macrophages or some cytokinnin production in the peritoneal cavity. In cancer chemotherapy the major problem encountered are myelosuppression and anaemia [124, 125]. The anaemia encountered in tumor bearing mice is mainly due to reduction in RBC or haemoglobin percentage and this may occur either due to iron deficiency or due to haemolytic or myelopathic conditions[126]. Treatment with the compound brought back the haemoglobin content, RBC and WBC cell count near to normal values. This indicates that compound III possess a significant anti-cancer activity.